U-500 Insulin Alert

MEDITECH PHA 5.6.7

EHR Update

U-500 Insulin Alert

The purpose of this project is to alert an ordering practitioner to acknowledge orders for high-concentration (U-500) insulin.

This project utilizes a screen to direct practitioners to double check when ordering U-500 insulin, ensure the order is ordered as units, and consider switching patients from vial to pen at discharge.

In Pharmacy, the pharmacist will review the practitioner's response when verifying CPOE orders for this type of insulin. If the order is being entered within Pharmacy the pharmacist will be required to answer the PHA Order Entry screen as 'Yes' before filing the order as complete.

Provider Workflow

When ordering U-500 insulin with the POM Rule attached, the practitioner will receive a pop-up alert to double check that they are knowingly ordering U-500 insulin, ensure the order is ordered as units, and tell them that they should consider switching patients from vial to pen at discharge.

Screen Sample



They will need to acknowledge the alert as 'Yes' before proceeding with submission of the order.

If the practitioner answers 'No' to the query they will get a message asking if the insulin was ordered in error and the steps to cancel the order, if so. The 'No' response will be removed after clicking the Ok button and the answer reentered. Only a response of 'Yes' will allow the order to be submitted.

CORP.PharmacyTeam@HCAHealthcare.com

HCA Healthcare®

Screen Sample



At any point during the ordering process, the provider can choose to exit the screen using **<F11>**, closure through **<X>**, or **<Esc>** key. After doing so, they will receive the Rule Check box, warning them that they will not be placing an order:

Screen Sample



Pharmacy Workflows

CPOE Order Verification

Orders placed through CPOE will require the pharmacist to review and acknowledge the text of the message displayed to the provider, as well as their response, prior to verifying U-500 High Concentration insulin orders.

Screen Sample



The alert will fire at the DOSE field and the user must respond ‘Yes’ to the alert before proceeding with verification. Answering ‘No’ will return the user to the DOSE field of the order where the alert will continue to fire until it is answered as ‘Yes’.

If the order needs to be put in pending status, the pharmacist will need to answer the acknowledgement alert with ‘Yes’ in order to proceed to that field on the ordering screen.

All information will be stored in the Print Order Audit. The provider’s response is also stored in the Query field of the order and will not require further review prior to verifying the order.

Pharmacy Order Entry

When entering U-500 High Concentrate Insulin orders via PHA Order Entry, the user must complete the single required query in the PHA Order Entry screen before the order can be filed.

Screen Sample



The pharmacist will use the <F9> lookup to choose ‘Yes’ or ‘No’ from the group responses associated with the query field.

Answering ‘No’ displays an error message that instructs the user to cancel the order if the drug was chosen in error and instruct the user to cancel the order, if so.

Screen Sample



Only a response of ‘Yes’ in the acknowledgement screen will allow the pharmacist to file the order as complete. The pharmacist can PEND the order without a response and contact the provider, if necessary.

All the screen verbiage, query response and the pharmacist entering the order is recorded in the Print Order of the medication.

Insulin Dose/Route Alert

MEDITECH PHA 5.6.7

EHR Update

Insulin Dose/Route Alert

The Insulin Dose/Route rule was created to display a message to the pharmacist for insulin orders with an order type of MED and a dose of >/=100 units with a route of SUBQ **or** on an order with a dose of >10 units with a route of IV.

Pharmacy Workflow Example

If the Pharmacist attempts to File an order with a MED order type and a dose of >/= 100 units with a SUBQ route of administration **or** an order with a dose of >10 units with a route of administration of IV, the alert will instruct the user that the order should be set in a PEND status for further review by the facility if needed.

Workflow #1: Pharmacist attempts to file order for >/= 100 units SUBQ Insulin

HCA.INSHD1 Alert Screen Sample



CORP.PharmacyTeam@HCAHealthcare.com

HCA Healthcare®

Workflow #2: Pharmacy attempts to file order for >10 units IV Insulin

HCA.INSHD1 Alert Screen Sample



With either workflow:

- If the user chooses ‘No’, they will be returned to the order screen so that they can PEND the order.
- If the user chooses ‘Yes’, they will be allowed to verify the order.

If the order is verified by the pharmacist, the rule’s information will be recorded in the Print Order audit trail:

Print Order Screen Sample



Heparin Dose/Route Alert

MEDITECH PHA 5.6.7

EHR Update

Heparin Dose/Route Alert

The heparin Dose/Route rule was created to alert the pharmacist if an order for heparin with a dose of 5000 or 7500 units was entered with a route of IV and is scheduled (SCH). This rule prevents potential medication errors by administering IV heparin on a scheduled basis, where orders are most likely meant to be administered SUBQ.

Pharmacy Workflow Example

If the Pharmacist attempts to File an order with a dose of 5000 or 7500 units and the route of administration is IV with a scheduled (SCH) order, the alert will instruct the user to verify the route of administration. The order should be set in a PEND status for further review by the facility if needed.

Workflow #1: Pharmacist attempts to file order with dose of 5000 units IV heparin

HCA.HEPSQ1 Alert Screen Sample



CORP.PharmacyTeam@HCAHealthcare.com

HCA Healthcare®

Workflow #2: Pharmacy attempts to file order with dose of 7500 units IV heparin

HCA.HEPSQ1 Alert Screen Sample



With either workflow:

- If the user chooses ‘No’, they will be returned to the order screen so that they can PEND the order.
- If the user chooses ‘Yes’, they will be allowed to verify the order.

If the order is verified by the pharmacist, the rule’s information will be recorded in the Print Order audit trail:

Print Order Screen Sample



Gestational Age Medication Dosing

MEDITECH 5.6.7 PHA Update

EHR Update

Gestational Age Dosing Updates for 2025.1 Release

For the 2025.1 Maintenance Release for Pharmacy, several updates have been made to the Gestational Age Dosing Screens, and these are outlined below:

1. Retired Ampicillin 50 mg/kg and Ampicillin 100 mg/kg and replaced with Ampicillin (Bacteremia) and Ampicillin (Meningitis) screens
2. Created screen for Penicillin G GBS Bacteremia
3. Created screen for Penicillin G GBS Meningitis
1. Created screen for Zosyn to only have Q8H option for everyone (removed attribute logic, same weight-based dose for all ages)
4. Created screen for Zidovudine PO HIV
5. Created screen for Fluconazole Inv Candidiasis
6. Made multiple changes to Dosing Chart:
    a. Change all instances of “0-29” to “</=29”
    b. Change “>44” to “>/=45”

For general information about the Gestational Age Medication Dosing workflow, please see the following content further below in this document.

Gestational Age Medication Dosing

The Gestational Age Medication Dosing screens are designed to assist clinicians in ordering an initial appropriate dose and administration frequency for selected medications based on the applicable gestational, postmenstrual, and/or postnatal ages of neonatal patients. This educational document will walk the end-user through the step-by-step process of completing a Gestational Age Dosing screen for an applicable medication.

See the standard Gestational Age Dosing Chart for standard medications at the end of this document.

CORP.PharmacyTeam@HCAHealthcare.com

HCA Healthcare®

Order Lookup



Step 1: Choose the patient.

Step 2: Select an order set with gestational age dosing, or a gestational age dosing order pre-built in the Orders lookup.

Step 3: Press <Enter> or click "Done" to generate the Gestational Age Dosing Screen.

Dosing Screen Formats

Medications dosed using Postmenstrual age – Example



Medications dosed using Gestational age – Example



There are 3 Dosing Screens that are dependent upon the age that is entered:

- Postmenstrual age
  - Postmenstrual age will calculate once all components are available.

- Gestational age
  - The Gestational age (weeks) and (days) fields are required.
  - If gestational age information is not available, it must be manually entered.
  - If gestational age information is available, that information will automatically populate into the gestational age fields.

HCA Healthcare®

Medications dosed using Postnatal age – Example



- Postnatal age
  - The postnatal age will automatically populate into the screen.

Gestational age update notification message



Note: Anytime a provider changes the Gestational age fields on the dosing screen, a message will be displayed (see image on left). If the Gestational age fields were blank prior to manually entering the information, no message displays.



Step 4: Once the dosing screen is complete with the necessary ages, press <Enter> or click "Ok" to reflex the medication order.



Step 5: You will be notified that a subsequent medication order has been reflexed

HCA Healthcare®



Step 6: The reflexed medication order will display on the Preview/Edit screen and may have required information to review.



Step 7: Within the Medication order, the Calculate Dose box will display. If needed, the dose or weight fields can be manually adjusted one last time.

Step 8: Press <Enter> or click "Ok" to continue out of the Calculate Dose screen.



Step 9: Press <Enter> or click "OK" to continue out of the medication order screen.

HCA Healthcare®





Step 10: For final review, the order and medication order display as "**New**" on the patient profile.

Step 11: To complete the ordering process, press <Submit>.

Note: When the ordering session is submitted, it will also file the Gestational Age (weeks) and (days) used during this session for any future orders and dosing of medications utilizing gestational age for this patient.

IMPORTANT: When a provider discontinues the medication, MEDITECH notifies the provider that the medication order is linked to a non-medication procedure. The order should also be discontinued. If the order is cancelled, the software logic wipes out the Gestational Age for future references in the Gestational Age Dosing tool.

The provider then must define the Gestational Age again even if it was previously saved within the dosing tool.

Error Messages

Gestational age (weeks): Error Message "< 20 weeks"



Gestational age (weeks): Error Message "> 43 weeks"



Gestational age (days): Error Message "> 6 days"



A few error messages could display during the gestational age medication ordering process if the age entered is not within the established boundaries.

- The gestational age (weeks) field will not accept a value of less than 20 weeks or greater than 43 weeks.

- The gestational age (days) field will not accept a value of more than 6.

Postnatal Age (days): Alert "greater than X# days".



Rule Check: Gestational Age Dosing Screen "Cancel" option.



Based on your facility's Postnatal age (days) background settings, you may receive an alert to consider infant dosing instead.

Note: The example shown has the age set at 32 days.

Selecting "Continue" will return the user back to the calculations screen. Selecting "OK" will result in a final confirmation message to cancel the order.

MetroNIDAZOLE ONLY: The postmenstrual age (weeks) field will not allow a calculation of less than 24 weeks and generate an alert.

HCA Healthcare®

MetroNIDAZOLE ONLY Rule Check: Postmenstrual age less than 24 weeks "Cancel" screen



Error Message "field required"



If the dosing screen is missing information (e.g., the gestational age), an error message will display as shown.

HCA Healthcare®

Gestational Age Dosing Chart

Note: Most of the medications listed below use postmenstrual age for dosing.

Fluconazole, Meropenem, and Meropenem meningitis use Gestational Age for dosing.

Cefepime, Ampicillin (Meningitis), Penicillin G GBS Bacteremia, and Penicillin G GBS Meningitis uses only Postnatal Age for dosing.

Key:
PMA – Postmenstrual Age
GA – Gestational Age

Reference for all dosing: NeoFax online (accessed ***5/4/22)*** Dosing approval granted by the Pediatric Pharmacy Advisory Board.

Medication	PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
Amikacin	</=29	0-7	14	48
	</=29	8-28	12	36
	</=29	>/= 29	12	24
	30-34	0-7	12	36
	30-34	>/= 8	12	24
	>/= 35	All	12	24
Ampicillin (Bacteremia) (Gestational Age only)	**GA (weeks)**	**Postnatal Age (days)**	**Dose (mg/kg)**	**Interval (hours)**
	</= 34	0-7	50	12
	</= 34	> 7	75	12
	> 34	All	50	8
Ampicillin (Meningitis) (Postnatal Age only)	**GA (weeks)**	**Postnatal Age (days)**	**Dose (mg/kg)**	**Interval (hours)**
	All	0-7	100	8
	All	> 7	75	6

CeFAZolin	PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
	</= 29	0-28	25	12
	</= 29	>28	25	8
	30-36	0-14	25	12
	30-36	>14	25	8
	37-44	0-7	25	12
	37-44	>7	25	8
	>/= 45	All	25	6

Cefepime (Postnatal Age only)	**GA (weeks)**	**Postnatal Age (days)**	**Dose (mg/kg)**	**Interval (hours)**
	All	</= 28	30	12
	All	>28	50	12

Cefotaxime	**PMA (weeks)**	**Postnatal Age (days)**	**Dose (mg/kg)**	**Interval (hours)**
	All	< 7	50	12
	< 32	>/= 7	50	8
	>/= 32	>/= 7	50	6

Clindamycin	**PMA (weeks)**	**Postnatal Age (days)**	**Dose (mg/kg)**	**Interval (hours)**
	</=29	0-28	5	12
	</=29	>28	5	8
	30-36	0-14	5	12
	30-36	>14	5	8
	37-44	0-7	5	12
	37-44	>7	5	8
	>/= 45	All	5	6

Clindamycin Necro Entero	**PMA (weeks)**	**Postnatal Age (days)**	**Dose (mg/kg)**	**Interval (hours)**
	</=29	0-28	7.5	12
	</=29	>28	7.5	8
	30-36	0-14	7.5	12
	30-36	>14	7.5	8
	37-44	0-7	7.5	12
	37-44	>7	7.5	8
	>/= 45	All	7.5	6

Fluconazole	**GA (weeks)**	**Postnatal Age (days)**	**Dose (mg/kg)**	**Interval (hours)**
	</=29	0-14	6	48
	</=29	>14	6	24
	>=30	0-7	6	48
	>=30	>7	6	24

Fluconazole Inv Candidiasis

GA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
</= 29	0-14	12	48
</= 29	>14	12	24
>/=30	0-7	12	48
>/=30	>7	12	24

Gentamicin

PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
</=29	0-7	5	48
</=29	8-28	4	36
</=29	>=29	4	24
30-34	0-7	4.5	36
30-34	>=8	4	24
>=35	All	4	24

Meropenem (Intra-abdominal and non-CNS infections)

GA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
<32	<14	20	12
<32	>/= 14	20	8
>/= 32	<14	20	8
>/= 32	>/= 14	30	8

Meropenem (Bacterial Meningitis)

GA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
<32	<14	40	12
<32	>/= 14	40	8
>/= 32	All	40	8

Metronidazole

PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
24-25	All	7.5	24
26-27	All	10	24
28-33	All	7.5	12
34-40	All	7.5	8
>/= 45	All	7.5	6

Nafcillin (Non-Meningitis)

PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
</= 29	0-28	25	12
</= 29	>28	25	8
30-36	0-14	25	12
30-36	>14	25	8
37-44	0-7	25	12
37-44	>7	25	8
>/= 45	All	25	6

Nafcillin (Meningitis)	PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
	</= 29	0-28	50	12
	</= 29	>28	50	8
	30-36	0-14	50	12
	30-36	>14	50	8
	37-44	0-7	50	12
	37-44	>7	50	8
	>/= 45	All	50	6

Oxacillin (Non-Meningitis)	PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
	</= 29	0-28	25	12
	</= 29	>28	25	8
	30-36	0-14	25	12
	30-36	>14	25	8
	37-44	0-7	25	12
	37-44	>7	25	8
	>/= 45	All	25	6
Oxacillin (Meningitis)	**PMA (weeks)**	**Postnatal Age (days)**	**Dose (mg/kg)**	**Interval (hours)**
	</= 29	0-28	50	12
	</= 29	>28	50	8
	30-36	0-14	50	12
	30-36	>14	50	8
	37-44	0-7	50	12
	37-44	>7	50	8
	>/= 45	All	50	6
Penicillin G (Bacteremia)	**PMA (weeks)**	**Postnatal Age (days)**	**Dose (units/kg)**	**Interval (hours)**
	</= 29	0-28	50,000	12
	</= 29	>28	50,000	8
	30-36	0-14	50,000	12
	30-36	>14	50,000	8
	37-44	0-7	50,000	12
	37-44	>7	50,000	8
	>/= 45	All	50,000	6
Penicillin G (GBS Bacteremia)	**GA (weeks)**	**Postnatal Age (days)**	**Dose (units/kg)**	**Interval (hours)**
	All	0-7	50,000	12
	All	>7	50,000	8

Penicillin G (Meningitis)	PMA (weeks)	Postnatal Age (days)	Dose (units/kg)	Interval (hours)
	</= 29	0-28	100,000	12
	</= 29	>28	100,000	8
	30-36	0-14	100,000	12
	30-36	>14	100,000	8
	37-44	0-7	100,000	12
	37-44	>7	100,000	8
	>/= 45	All	100,000	6

Penicillin G (GBS Meningitis)	GA (weeks)	Postnatal Age (days)	Dose (units/kg)	Interval (hours)
	All	0-7	150,000	8
	All	>7	125,000	6

Tobramycin	PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
	</= 29	0-7	5	48
	</= 29	8-28	4	36
	</= 29	>/= 29	4	24
	30-34	0-7	4.5	36
	30-34	>/= 8	4	24
	>/= 35	All	4	24

Vancomycin (Non-Meningitis)	PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
	</=29	0-14	10	18
	</=29	>14	10	12
	30-36	0-14	10	12
	30-36	>14	10	8
	37-44	0-7	10	12
	37-44	>7	10	8
	>/= 45	All	10	6

Vancomycin (Meningitis)	PMA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
	</=29	0-14	15	18
	</=29	>14	15	12
	30-36	0-14	15	12
	30-36	>14	15	8
	37-44	0-7	15	12
	37-44	>7	15	8
	>/= 45	All	15	6

Zidovudine PO HIV	GA (weeks)	Postnatal Age (days)	Dose (mg/kg)	Interval (hours)
	<30	</=28	2	12
	<30	29-56	3	12
	<30	>56	12	12
	30-34	<15	2	12
	30-34	15-42	3	12
	30-34	>42	12	12
	>/=35	</=28	4	12
	>/=35	>28	12	12
Zosyn 100 mg/kg	**GA (weeks)**	**Postnatal Age (days)**	**Dose (mg/kg)**	**Interval (hours)**
	All	All	100	8

Edoxaban Verbiage Updates

MEDITECH PHA 5.6.7

EHR Update

Edoxaban Verbiage Updates

All Direct Oral Anticoagulant (DOAC) medications have the potential to falsely elevate INR due to an interaction with the lab assay. An alert message will be added to the edoxaban screens' workflow to provide similar safety and ordering alert messaging for all DOACs. The same alert message from the apixaban and rivaroxaban screens' workflow for INR assay interaction will be applied to edoxaban.

Below are the screens where the verbiage has been updated. Note: for a review of the workflow for the original edoxaban project, please see the workflow section in the Administration Guide for the project.

Provider Indication Screen – Verbiage Update



CORP.PharmacyTeam@HCAHealthcare.com

HCA Healthcare®

Pharmacy Order Verification – DOSE field indication alert



Pharmacy Order Entry – MED field criteria alert



Dabigatran Verbiage Updates

MEDITECH PHA 5.6.7

EHR Update

Dabigatran Verbiage Updates

All Direct Oral Anticoagulant (DOAC) medications have the potential to falsely elevate INR due to interaction with the lab assay. An alert message will be added to the dabigatran screens' workflow to provide similar safety and ordering alert messaging for all DOACs. The same alert message from the apixaban and rivaroxaban screens' workflow for INR assay interaction will be applied to dabigatran.

Below are the screens where the verbiage has been updated. Note: for a review of the workflow for the original dabigatran project, please see the workflow section in the Administration Guide for the project.

Provider Indication Screen – Verbiage Update



CORP.PharmacyTeam@HCAHealthcare.com

HCA Healthcare®

Pharmacy Order Verification – DOSE field indication alert



Pharmacy Order Entry – MED field criteria alert



COVID-19 Tocilizumab Indications Project Update

Tocilizumab is now an FDA approved treatment for COVID-19 for adult patients. EUA documentation is no longer required for adult patients (EUA documentation IS still required for pediatric patients). To help mitigate alert fatigue, due to additional steps and popups which are no longer needed, screens have been updated to reflect the approved status of Tocilizumab for COVID-19 treatment for adult patients, but still require EUA workflow for pediatric patients.

Workflow Examples

Ordering Provider

From an Order String

- When ordering tocilizumab, the provider will select a string.

Screen Sample



- Once the provider selects the string and clicks <Done>, they will receive the following Point-n-Click screen with a required Rx indication field.

Indication Screen Sample



- If the provider selects **CAR T-Cell induced Cytokine Release Syndrome, Juvenile-arthritis or rheumatoid arthritis, Scleroderma/Systemic Sclerosis, or Temporal arteritis** as the indication, the screen automatically closes.
- If the provider selects **Other** as the indication, the Other Rx Indication field requires a free-text response. The provider can click the <Enter> key, <End> or <Ok> to complete the screen.

Screen Sample



- If the provider selects **COVID-19** as the indication, they are taken to a new page to complete an attestation and EUA queries, if applicable.

Screen Sample



- Once the provider has reviewed the criteria and selected from the 2 options presented,
  - the screen will close for patients 18 years or older
  - the cursor will advance to the EUA queries for patients less than 18
    - Each of the EUA queries are required and only accept an answer of Yes.

Screen Sample



- After answering the EUA questions, the provider can print the patient fact sheet in either English or Spanish.

Screen Sample



- The provider must select Yes in one of the Print queries. The EUA fact sheet opens in the default browser.
    - Once the respective page loads, the provider should print the EUA fact sheet and then return to MEDITECH to continue with the medication ordering process.
        - If the provider prints the EUA fact sheet in English, they must click <End>, <Ok> or <green checkmark> to complete the screen.
        - If the provider prints the Spanish EUA fact sheet, the screen will automatically close as the final field has been addressed and the provider may proceed with their ordering session.

- At any point,should the provider attempt to complete either the indication or attestation/EUA screens without all required fields being completed, as applicable, they receive an error message.

Screen Sample



- At any point during the ordering process, the provider can click the <red X> to close the screen. Doing so cancels the order, and the provider receives a notification as such.

Screen Sample



Pharmacy

Verifying an ePOM Order (CPOE)

- As the pharmacist processes through an UNV order, at the DOSE field an alert message containing the provider-selected response will prompt for review. The information will show a little differently based on the indication the provider selected.
    - For **CAR T-Cell induced Cytokine Release Syndrome, Juvenile-arthritis or rheumatoid arthritis, Scleroderma/Systemic Sclerosis, or Temporal arteritis** indications, the following alert message presents to the pharmacist for review.

Screen Sample



- For an indication of **Other**, the alert message to the pharmacist displays the same information as above and also includes the free-texted response from the provider.

Screen Sample



- For a **COVID-19** indication, the following alert message presents to the pharmacist for review.

Screen Sample



- On any of the alerts, the pharmacist can select <Yes> or <No> to continue but cannot bypass the screen by pressing the <Enter> key.
- The DOSE rule, along with all associated information in the alerts, is recorded in the Audit Trail.

PHA Order Entry

- When a pharmacist enters a NEW tocilizumab order through PHA Process Orders, he/she receives an alert message at the DOSE field containing general medication information.

Screen Sample



- The pharmacist can select <Yes> or <No> to continue but cannot bypass the message by pressing the <Enter> key.
- An indication is required on the Order Entry Query screen to complete an order. If the pharmacist attempts to file a new order that does not yet contain an indication, he/she will receive an error that a required field is missing.

Screen Sample

- After entering through the error, the cursor goes to the Query field where the pharmacist will type a Y in the Edit field to access the Order Entry Query field.

- They will then press <F9> in the Rx Indication field to select an indication.

Order Entry Query Screen Sample



Indication Lookup Screen Sample



- If **CAR-T induced CRS**, **Juvenile/Rheuma Arthritis**, **Scleroderm/Syst Sclerosis**, or **Temporal arteritis** is selected as the indication, the screen will auto-close after the selection is made.
- If **Other** is selected as the indication, the Other Rx Indication field requires you to enter a free-text response. Next, press <Enter> or <F12> to complete the screen.

- If **COVID-19** is selected as the indication, the cursor advances to the “Provider reviewed criteria for use and:” field. Once the cursor is in this field, the highlighted text displays for the pharmacist directing them to press <Shift + F8> to view the COVID-19 criteria for use.

Screen Sample



- After selection is made, the screen will close if the patient is 18 years or older or remain open requiring completion of the EUA queries for patients less than 18.
- If the patient is less than 18 years old and the provider has not provided attestation that the patient meets criteria for use as well as EUA documentation, the pharmacist should PEND the order and contact the ordering provider.
- All queries completed in the screen, along with the pharmacist review of the DOSE alert, will log in the Print Order.